Despite earnings, investors cannot help but notice the continuing impact of the strong dollar on tech revenues.» Read More
Here's where the stock market and baseball meet, just in time for the World Series as well as a likely volatile time ahead on Wall Street.
The Fed is expected to end its quantitative easing program—the much-anticipated action that's been at the very heart of the market's fears.
If you’re saving for retirement and panicked by the volatility in the market, at least one pro questions your Street smarts.
Pro investor Ralph Acampora sees no reason for the rally to end. “October was its obnoxious self,” he said. He likes November better.
In the wake of a deadly attack this week in Canada, traders have been forced to reconcile the potential of increased terrorism. What you must know?
Oil companies have yet to cut production and capital expenditures amid low oil prices. But if oil drops furthers, that could change.
His company just suffered a setback, but this CEO is still tops with the Harvard Business Review.
Investors were closely monitoring developments in the attempts to contain Ebola after a new case was diagnosed in New York City.
Crude oil continues to flirt with the key $80 per barrel level, signaling another possible sharp leg down in price in the coming weeks.
There's a slew of things pros on the Street believe that just don't seem to make a lot of sense.
Wall Streeters traded their Bloomberg terminals for guitars and sunglasses to rock out for a good cause this week.
The stock market is acting as if the mid-October swoon never happened, despite a general—and fairly recent—sense of caution on Wall Street.
Turney Duff worked at billion-dollar hedge funds. But when he wants to know what's hot—like Apple or Samsung?—he consults these pint-size analysts.
But long time stock bull Jeremy Siegel tells CNBC it looks like the stock market hit its recent bottom last week.
Some of the names on the move ahead of the open.
One survey found that gender diversity on corporate boards is correlated to steady, positive performance.
U.S. drugmaker Pfizer's new $11 billion share repurchase plan is deflating expectations that it will make a new bid for AstraZeneca.
Amazon's huge earnings miss may be the last straw for investors.
Despite the swings in the market, favoring fixed-income or bond funds over equity or stocks in a retirement account could be a mistake. Here's why.
Stocks head into Friday on track for the best weekly performance in 22 months, yet new Ebola fears and other geopolitical headlines could be wild cards.